Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Background Diminished growth hormone ( GH ) is associated with impaired endothelial function and fibrinolysis. GH ‐releasing hormone is the primary stimulus for GH secretion and a substrate of dipeptidyl peptidase‐4. We tested the hypothesis that dipeptidyl peptidase‐4 inhibition with sitagliptin increases stimulated GH secretion, vasodilation, and tissue plasminogen activator ( tPA ) activity. Methods and Results Healthy adults participated in a 2‐part double‐blind, randomized, placebo‐controlled, crossover study. First, 39 patients (29 women) received sitagliptin or placebo on each of 2 days separated by a washout. One hour after study drug, blood was sampled and then arginine (30 g IV) was given to stimulate GH . Vasodilation was assessed by plethysmography and blood sampled for 150 minutes. Following a washout, 19 of the original 29 women received sitagliptin alone versus sitagliptin plus antagonist to delineate GH receptor ( GHR )– (n=5), nitric oxide– (n=7), or glucagon‐like peptide‐1 receptor– (n=7) dependent effects. Sitagliptin enhanced stimulated GH secretion ( P <0.01 versus placebo, for 30 minutes) and free insulin–like growth factor‐1 ( P <0.001 versus placebo, after adjustment for baseline) in women. Vasodilation and tPA increased in all patients, but sitagliptin enhanced vasodilation ( P =0.01 versus placebo) and increased tPA ( P <0.001) in women only. GHR blockade decreased free insulin–like growth factor‐1 ( P =0.04 versus sitagliptin alone) and increased stimulated GH ( P <0.01), but decreased vascular resistance ( P =0.01) such that nadir vascular resistance correlated inversely with GH ( r s =−0.90, P <0.001). GHR blockade suppressed tPA . Neither nitric oxide nor glucagon‐like peptide‐1 receptor blockade affected vasodilation or tPA . Conclusions Sitagliptin enhances stimulated GH , vasodilation, and fibrinolysis in women. During sitagliptin, increases in free insulin–like growth factor‐1 and tPA occur via the GHR , whereas vasodilation correlates with GH but occurs through a GHR ‐independent mechanism. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01701973.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,810
Funders: Vanderbilt University, Georgia Clinical and Translational Science Alliance, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
Awards: G1182793083, G2209161966, G4425699080, Effect of dipeptidyl peptidase 4 inhibition on growth hormone secretion, G5679716143, G7190853823, The Vanderbilt Institute for Clinical and Translational Research (VICTR), Cardiovascular Consequences of Peptidase Inhibition, G9000033427, Vanderbilt Institute for Clinical and Translational Research (VICTR), Clinical Pharmacology Training Program, Vanderbilt Diabetes Research Center, Research Training in Diabetes and Endocrinology, Institutional Career Development Core, G95160140
OpenAlex ID: W2794401990